Dr. Jim on Real-World Quality of Life Outcomes With Axi-Cel in R/R LBCL

Heather Jim, PhD, discusses a real-world analysis, examining the quality of life outcomes seen with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.

Heather Jim, PhD, program co-leader, Health Outcomes and Behavior Program, Moffitt Cancer Center, discusses a real-world analysis, examining the quality of life outcomes seen with axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed/refractory large B-cell lymphoma (LBCL).

Investigators assessed 53 patients’ quality of life prior to treatment with CAR T-cell therapy, followed by additional assessments following treatment with CAR T-cell therapy at 14, 30, 60, 90, 180, and 360 days, Jim explains. It was found that most patients quality of life improved, despite a dip in quality of life at baseline, Jim adds.

Patients’ quality of life was determined by physical functioning, role functioning, social functioning, and global quality of life, Jim continues. Notably, by 1 year, the same patients were reporting a quality of life comparable to patients who never had cancer, Jim concludes.

Related Videos
View All
Related Content